Effect of Oral Midodrine Along with Standard Medical Treatment on Recovery from Shock in Patients with Liver Cirrhosis

oral midodrine plus standard medical therapy vs standard medical therapy for the management of the circulatory shock in patients with cirrhosis of liver:A RANDOMISED CONTROLLED OPEN LABEL STUDY - Nill

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112955

Enrollment

Registered

2026-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K740- Hepatic fibrosis

Interventions

Intervention1: Oral midodrine plus standard medical therapy: Oral midodrine 10mg tds for 72 hours , not more than 30 mg/ day plus standard medical therapy for circulatory shock (norepinephrine, vasopr

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient age more than or equal to 18 years. 2. Patient is a diagnosed case of cirrhotic liver diseases 3. Patient in circulatory shock defined by MAP less than 65mmHg after adequate fluid resuscitation . 4. Patients ,or their legal guardian who provide informed consent for participation in study.

Exclusion criteria

Exclusion criteria: 1 . Hypovolemic shock.(where the trearting clinician deems the current shock is due to volume lose). 2. Severe renal function requiring hemodialysis at presentation. 3. Pregnancy and lactating females. 4. Known Hypersensitivity to midodrine. 5. known Patient of thyrotoxicosis,hyperthyroidism or pheochromocytoma. 6. Left ventricular ejection fraction less than 30 percent.

Design outcomes

Primary

Measure	Time frame
To Assess Percentage of patients attaining a Mean Arterial Pressure of more than equal to 65 mmHg within 24 hours when using Midodrine plus Standard therapy compared to Standard therapy alone in the management of Shock in patients with cirrhosis of liverTimepoint: 0 ,24 hours	—

Secondary

Measure	Time frame
1. To look for Responders in Midodrine group in achieving 10 percentage reduction in the doses on Norepinephrine/other vasopressors needed to maintain a MAP of 65 mmHg in Shock patients with cirrhosis. 2.To look for percentage of patients in which there is a need to reinitiate Vasopressors within 72 hours 3.To assess Mortality rates at 72 hours,7 days, and in-hospital mortality, lcu admission and length of hospital stay in both the groups 4.Safety of Midodrine in 72hrs in terms of(a) Drop in heart rate from baseline. (b) Development of urinary retention. (c) Any allergic/anaphylaxis manifestationTimepoint: 0,24 hours,72hours,7 days	—

Measure

Time frame

1. To look for Responders in Midodrine group in achieving 10 percentage reduction in the doses on Norepinephrine/other vasopressors needed to maintain a MAP of 65 mmHg in Shock patients with cirrhosis. 2.To look for percentage of patients in which there is a need to reinitiate Vasopressors within 72 hours 3.To assess Mortality rates at 72 hours,7 days, and in-hospital mortality, lcu admission and length of hospital stay in both the groups 4.Safety of Midodrine in 72hrs in terms of(a) Drop in heart rate from baseline. (b) Development of urinary retention. (c) Any allergic/anaphylaxis manifestationTimepoint: 0,24 hours,72hours,7 days

—

Countries

India

Contacts

Public ContactNAYER JAMSHED

All India Institute of Medical Sciences New Delhi

Jamshednayer@gmail.com9990345682

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026